Results 141 to 150 of about 809,966 (374)

Novel CT radiomics models for the postoperative prediction of early recurrence of resectable pancreatic adenocarcinoma: A single‐center retrospective study in China

open access: yesJournal of Applied Clinical Medical Physics, EarlyView.
Abstract Purpose To assess the predictive capability of CT radiomics features for early recurrence (ER) of pancreatic ductal adenocarcinoma (PDAC). Methods Postoperative PDAC patients were retrospectively selected, all of whom had undergone preoperative CT imaging and surgery. Both patients with resectable or borderline‐resectable pancreatic cancer met
Xinze Du   +7 more
wiley   +1 more source

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

open access: yesNew England Journal of Medicine, 2004
BACKGROUND On the basis of a previous meta-analysis, the International Adjuvant Lung Cancer Trial was designed to evaluate the effect of cisplatin-based adjuvant chemotherapy on survival after complete resection of non-small-cell lung cancer.
R. Arriagada   +5 more
semanticscholar   +1 more source

Liraglutide for idiopathic intracranial hypertension: a real‐world propensity score‐matched study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Abstract Objective Idiopathic intracranial hypertension (IIH) is a neurological disorder predominantly affecting young women with obesity, characterized by elevated intracranial pressure. While current treatments include weight loss counseling, medical therapies, and surgical interventions, their limitations necessitate exploring novel therapeutic ...
Ahmed Y. Azzam   +13 more
wiley   +1 more source

Cancer Vaccine Adjuvant Name Recognition from Biomedical Literature using Large Language Models [PDF]

open access: yesarXiv
Motivation: An adjuvant is a chemical incorporated into vaccines that enhances their efficacy by improving the immune response. Identifying adjuvant names from cancer vaccine studies is essential for furthering research and enhancing immunotherapies.
arxiv  

Are Thousands of Samples Really Needed to Generate Robust Gene-List for Prediction of Cancer Outcome? [PDF]

open access: yesarXiv, 2016
The prediction of cancer prognosis and metastatic potential immediately after the initial diagnoses is a major challenge in current clinical research. The relevance of such a signature is clear, as it will free many patients from the agony and toxic side-effects associated with the adjuvant chemotherapy automatically and sometimes carelessly subscribed
arxiv  

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

open access: yesNew England Journal of Medicine, 2003
BACKGROUND Colon cancers with high-frequency microsatellite instability have clinical and pathological features that distinguish them from microsatellite-stable tumors. We investigated the usefulness of microsatellite-instability status as a predictor of
C. Ribic   +12 more
semanticscholar   +1 more source

Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Abstract Cases of myelin oligodendrocyte glycoprotein (MOG) antibody‐associated disease (MOGAD) co‐occurring with neoplasms have been reported. In this international, retrospective cohort study in South Korea and the USA, 16 of 445 (3.6%) patients with MOGAD had concurrent neoplasm within 2 years of MOGAD onset, resulting in a standardized incidence ...
Young Nam Kwon   +24 more
wiley   +1 more source

Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer

open access: yesBritish Journal of Surgery, 2018
Although some retrospective studies have suggested the value of adjuvant therapy, no recommended standard exists in bile duct cancer. The aim of this study was to test the hypothesis that adjuvant gemcitabine chemotherapy would improve survival ...
T. Ebata   +48 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy